TG THERAPEUTICS, INC.: 10-K filed 2018-03-15
What TG THERAPEUTICS, INC. reported in its annual report filed 2018-03-15 (fiscal FY 2017): 24 published measures, 76 facts as tagged in accession 0001654954-18-002638.
This filing
- Form
- 10-K (annual report)
- Filed
- 2018-03-15
- Fiscal period
- fiscal FY 2017
- Accession
- 0001654954-18-002638 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All TG THERAPEUTICS, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-12-31 | 97,381,536 | USD | |
| At 2016-12-31 | 54,781,547 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-12-31 | 30,388,481 | USD | |
| At 2016-12-31 | 18,913,745 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-12-31 | 56,717,847 | USD | |
| At 2016-12-31 | 25,031,280 | USD | |
| At 2015-12-31 | 55,061,329 | USD | |
| At 2014-12-31 | 55,713,784 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-10-01 to 2017-12-31 | -30,859,767 | USD | 92 |
| 2017-07-01 to 2017-09-30 | -31,535,652 | USD | 92 |
| 2017-04-01 to 2017-06-30 | -28,353,084 | USD | 91 |
| 2017-01-01 to 2017-03-31 | -27,727,509 | USD | 90 |
| 2016-10-01 to 2016-12-31 | -23,674,143 | USD | 92 |
| 2016-07-01 to 2016-09-30 | -24,831,027 | USD | 92 |
| 2016-04-01 to 2016-06-30 | -15,899,062 | USD | 91 |
| 2016-01-01 to 2016-03-31 | -13,848,662 | USD | 91 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-12-31 | 2,227 | USD | 365 |
| 2016-01-01 to 2016-12-31 | 343,985 | USD | 366 |
| 2015-01-01 to 2015-12-31 | 42,217 | USD | 365 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-12-31 | -354,862,832 | USD | |
| At 2016-12-31 | -236,386,820 | USD |
Income tax expense or benefit
Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-12-31 | 0 | USD | 365 |
| 2016-01-01 to 2016-12-31 | 0 | USD | 366 |
| 2015-01-01 to 2015-12-31 | 0 | USD | 365 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-12-31 | 248,020 | USD | |
| At 2016-12-31 | 328,148 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-12-31 | 15,945,284 | USD | 365 |
| 2016-01-01 to 2016-12-31 | 7,509,999 | USD | 366 |
| 2015-01-01 to 2015-12-31 | 15,697,092 | USD | 365 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-12-31 | -118,711,751 | USD | 365 |
| 2016-01-01 to 2016-12-31 | -78,969,128 | USD | 366 |
| 2015-01-01 to 2015-12-31 | -63,180,016 | USD | 365 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-12-31 | 93,317,400 | USD | |
| At 2016-12-31 | 50,864,144 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-12-31 | 27,957,213 | USD | |
| At 2016-12-31 | 16,878,440 | USD |
Goodwill carrying amount
Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-12-31 | 799,391 | USD | |
| At 2016-12-31 | 799,391 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-10-01 to 2017-12-31 | 31,072,826 | USD | 92 |
| 2017-01-01 to 2017-12-31 | 118,864,132 | USD | 365 |
| 2017-07-01 to 2017-09-30 | 31,623,323 | USD | 92 |
| 2017-04-01 to 2017-06-30 | 28,463,466 | USD | 91 |
| 2017-01-01 to 2017-03-31 | 27,704,517 | USD | 90 |
| 2016-10-01 to 2016-12-31 | 24,066,153 | USD | 92 |
| 2016-01-01 to 2016-12-31 | 79,121,509 | USD | 366 |
| 2016-07-01 to 2016-09-30 | 24,963,567 | USD | 92 |
| 2016-04-01 to 2016-06-30 | 16,061,538 | USD | 91 |
| 2016-01-01 to 2016-03-31 | 14,030,251 | USD | 91 |
| 2015-01-01 to 2015-12-31 | 63,332,397 | USD | 365 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-12-31 | 102,532,850 | USD | 365 |
| 2016-01-01 to 2016-12-31 | 69,232,174 | USD | 366 |
| 2015-01-01 to 2015-12-31 | 47,707,223 | USD | 365 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-12-31 | 73,140,441 | shares | |
| At 2016-12-31 | 56,779,114 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-12-31 | 422,017,042 | USD | |
| At 2016-12-31 | 272,432,139 | USD |
Total equity including noncontrolling interests
Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-12-31 | 66,993,055 | USD | |
| At 2016-12-31 | 35,867,802 | USD | |
| At 2015-12-31 | 101,573,302 | USD | |
| At 2014-12-31 | 80,101,884 | USD |
Other noncurrent assets
Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-12-31 | 0 | USD | |
| At 2016-12-31 | 164,375 | USD |
Net deferred tax assets
Deferred tax assets after the valuation allowance. Realization depends on future taxable income, so the balance is not a receivable from tax authorities.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-12-31 | 0 | USD | |
| At 2016-12-31 | 0 | USD |
Profit or loss including noncontrolling interests
Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-12-31 | -118,476,012 | USD | 365 |
| 2016-01-01 to 2016-12-31 | -78,252,894 | USD | 366 |
| 2015-01-01 to 2015-12-31 | -62,948,646 | USD | 365 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-12-31 | 16,331,282 | USD | 365 |
| 2016-01-01 to 2016-12-31 | 9,889,335 | USD | 366 |
| 2015-01-01 to 2015-12-31 | 15,625,174 | USD | 365 |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-12-31 | 82,355 | USD | 365 |
| 2016-01-01 to 2016-12-31 | 62,960 | USD | 366 |
| 2015-01-01 to 2015-12-31 | 15,452 | USD | 365 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-12-31 | 235,739 | USD | 365 |
| 2016-01-01 to 2016-12-31 | 716,234 | USD | 366 |
| 2015-01-01 to 2015-12-31 | 231,370 | USD | 365 |
Inspect the source
- Entity
- TG THERAPEUTICS, INC. / CIK 0001001316
- Captured
- 2026-09-20T05:11:16.212Z
- SEC response SHA-256
153d276440c1903144d2ca193676af4b7014428a3e4b5524efe33528427880b3
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001001316.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))